Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients
1 other identifier
interventional
120
1 country
1
Brief Summary
When considering occult infections during the diagnostic workup of inflammation in Hemodialysis (HD) patients, the urine-deprived bladder is frequently dismissed as potential site of infection. The urinary tract, even in end stage renal disease (ESRD) patients on hemodialysis may represent a significant reservoir for infection. Delayed diagnosis is a relevant issue because the urinary tract is often overlooked as a source of infection in dialysis patients, especially because of absence of urinary tract infection (UTI) symptoms in HD patients. Contributing factors to asymptomatic UTI in HD patients include the presence of low urine volume, bladder stasis, and the fact that UTI symptoms are mostly related to voiding, which is reduced or absent in these patients. Persistence of asymptomatic bacteriuria and UTI may be related to higher levels of inflammatory markers in HD population. In view of the association between cardiovascular disease and cardio-vascular and all-cause mortality with inflammation, as expressed by elevated CRP and/or IL-6 levels in HD patients, the investigators questioned whether presence of asymptomatic UTI could contribute to elevated levels of inflammatory markers in patients with ESRD on maintenance HD therapy. Such a finding would provide a potential link between a treatable infection and a potential cardiovascular risk factor in this population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2011
CompletedFirst Submitted
Initial submission to the registry
March 15, 2012
CompletedFirst Posted
Study publicly available on registry
April 4, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2013
CompletedApril 4, 2012
March 1, 2012
2 years
March 15, 2012
April 3, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in serum inflammatory markers (CRP, IL-6)
3 months, 6 months, and 12 months
Secondary Outcomes (1)
Cardio-vascular events
3 months, 6 months and 12 months
Study Arms (2)
Patients with positive culture, treatment group
ACTIVE COMPARATORThese asymptomatic patients with positive urinary culture, seven days of antibiotics will be given according to the bacteriogram sensitivity.
Patients with positive culture, observation only
NO INTERVENTIONThese asymptomatic patients with positive urine culture, will be observed only during the study period.
Interventions
In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
Eligibility Criteria
You may qualify if:
- Male or female, age \> 18 years, in chronic hemodialysis treatment at least 3 months
- Stable and adequate hemodialysis treatment three months prior to participation in study as defined by Kt/V \> 1.2 and hemodialysis performed at least 3 times weekly
- Patients with native A-V Fistula or graft
- Informed consent obtained before any trial-related activities
You may not qualify if:
- Patients with an indwelling catheters
- Patients with periodontitis
- Patients with diabetic foot
- Patients with active malignant disease or liver cirrhosis
- Patients on chronic treatment with steroids on doses \> 10 mg/day Prednisone (or equivalent)
- Patients treated with immunosuppressive agents
- Patients suffering from
- Acute vasculitis
- Severe systemic infections
- Heart failure (NYHA class III-IV)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nephrology Department, Assaf Harofeh Medical Center
Ẕerifin, 70300, Israel
Related Publications (1)
Beberashvili I, Sinuani I, Azar A, Yasur H, Shapiro G, Feldman L, Averbukh Z, Weissgarten J. IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol. 2011 Sep;6(9):2253-63. doi: 10.2215/CJN.01770211. Epub 2011 Aug 18.
PMID: 21852667BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 15, 2012
First Posted
April 4, 2012
Study Start
December 1, 2011
Primary Completion
December 1, 2013
Last Updated
April 4, 2012
Record last verified: 2012-03